ODDITY Tech Ltd. announced record financial results for the fourth quarter and full year ended December 31, 2024. For Q4 2024, net revenue reached $124 million, a 27% increase year-over-year, with adjusted diluted EPS of $0.20 and GAAP net income of $5.3 million, or $0.09 per share.
The full year 2024 saw net revenue of $647 million, up 27% year-over-year, and adjusted EBITDA of $164 million, representing a 25.3% margin. Adjusted diluted EPS for the full year was $1.90, and the company generated $127 million in free cash flow, highlighting its profitable growth model.
Looking ahead, ODDITY provided robust guidance for 2025, projecting full-year net revenue between $776 million and $785 million, representing 20% to 21% year-over-year growth. Adjusted EBITDA is expected to be between $155 million and $158 million, with an adjusted diluted EPS forecast of $1.94 to $1.98.
The company outlined key initiatives for 2025, including the planned launch of Brand 3 (METHODIQ), a medical-grade telehealth platform for dermatology, in Q4 2025. Additionally, ODDITY plans to launch Brand 4 in 2026 and continue expanding ODDITY Labs, its biotechnology center, to strengthen its competitive position and drive future growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.